Company intelligence / Profile preview

G2B Pharma

Corte Madera, California, United States

Ownership: Private
Development stage: Other

Overview

The company's lead program, G2B011, demonstrated rapid and high absorption of nasal epinephrine in a 2013 proof-of-concept study, comparable to standard epinephrine auto-injector (EpiPen®); targeted as a non-injectable alternative for anaphylaxis.

Therapeutic areas: Immunology
Modalities: Small moleculeNasal delivery device
Industry: Biotech

Drug pipeline

1 asset

G2B011

Preclinical

Partnerships

Sosei Group Corporation (project financing and development partnership)Shin Nippon Biomedical Laboratories (SNBL; nasal delivery technology licensing and co-development)

Beyond the preview

Go deeper on G2B Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G2B Pharma.

Explore the full profile